Holen Sie sich die Stockscreener-App
20.02
2.01%
-0.41
Handel nachbörslich:
20.40
0.38
+1.90%
Schlusskurs vom Vortag:
$20.43
Offen:
$20.33
24-Stunden-Volumen:
201.87K
Relative Volume:
0.82
Marktkapitalisierung:
$300.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.47M
KGV:
-20.22
EPS:
-0.99
Netto-Cashflow:
$-52.33M
1W Leistung:
-19.05%
1M Leistung:
-0.10%
6M Leistung:
-13.03%
1J Leistung:
+218.28%
1-Tages-Spanne:
$19.12
$20.52
1-Wochen-Bereich:
$19.12
$24.90
52-Wochen-Spanne:
$4.00
$31.01
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Firmenname
Jasper Therapeutics Inc
Sektor
Branche
Telefon
(650) 549-1400
Adresse
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Vergleichen Sie JSPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| JSPR | 20.02 | 300.33M | 0 | -64.47M | -52.33M | -0.99 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-11 | Eingeleitet | CapitalOne | Overweight |
| 2022-02-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Credit Suisse | Outperform |
| 2021-10-21 | Eingeleitet | William Blair | Outperform |
| 2021-10-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-13 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma (NASDAQ:JSPR) - Seeking Alpha
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate - Yahoo Finance
Is Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes mast cell stock - Investing.com
Jasper Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Jasper Therapeutics to Present Briquilimab Updates at Major Healthcare Conferences | JSPR Stock News - StockTitan
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $74.86 - MarketBeat
Stifel Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation - MSN
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) News: Jasper Therapeutics, Inc. Reports Third Quarter 2024 Results - Defense World
Analysts Bullish on Jasper Therapeutics as Briquilimab Trials Show Promise - GuruFocus.com
Jasper Therapeutics Advances in Antibody Therapy Development - TipRanks
Jasper Therapeutics Inc (JSPR) Quarterly 10-Q Report - Quartzy
McDonald's Corp (MCD-N) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail
Nasdaq Other Finance Index (OFIN) QuotePress Release - The Globe and Mail
(JSPR) Long Term Investment Analysis - Stock Traders Daily
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
Net Present Value Model: Jasper Therapeutics Inc’s Briquilimab - GlobalData
JSPRJasper Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Long Term Trading Analysis for (JSPR) - Stock Traders Daily
Jasper Therapeutics' SWOT analysis: briquilimab stock shows promise amid challenges - Investing.com
Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from HC Wainwright - MarketBeat
Jasper Therapeutics to Present Preclinical Briquilimab Data - GlobeNewswire
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - StockTitan
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria - GlobeNewswire
Molina Healthcare (MOH) Set to Announce Earnings on Wednesday - Defense World
Analysts Set Rush Street Interactive, Inc. (NYSE:RSI) Target Price at $11.17 - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $74.86 Consensus Target Price from Brokerages - MarketBeat
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline News & Insights
Jasper Therapeutics (NASDAQ:JSPR) Rating Reiterated by HC Wainwright - Defense World
Metagenomi (NASDAQ:MGX) Stock Rating Reaffirmed by HC Wainwright - Defense World
JMP Securities Reiterates Market Outperform Rating for Jasper Therapeutics (NASDAQ:JSPR) - Defense World
JMP Securities analysts initates a Mkt outperform rating for Jasper Therapeutics Inc (JSPR) - Knox Daily
Analysts review Ares Capital Corp’s rating - Knox Daily
Jasper Therapeutics shares keep buy rating with positive study results By Investing.com - Investing.com Canada
DoubleVerify Holdings Inc [DV] stock was sold by Allais Nicola T at the price of US$30365.0 - Knox Daily
When (JSPR) Moves Investors should Listen - Stock Traders Daily
Jasper Therapeutics Inc (JSPR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Jasper gains 11% on data for briquilimab in urticaria (NASDAQ:JSPR) - Seeking Alpha
Jasper Therapeutics shares hold as Oppenheimer maintains $80 target By Investing.com - Investing.com Canada
Jasper Therapeutics shares hold as BTIG maintains $90 target By Investing.com - Investing.com UK
You Should Read This Analysis Before Investing in Jasper Therapeutics Inc (NASDAQ:JSPR) - US Post News
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? - Yahoo Finance
Jasper reports promising early results in urticaria study - Investing.com
Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday? - Benzinga
Jasper Therapeutics Stock Gains on Strong Briquilimab Trial Results - MarketWatch
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewswire
Jasper reports promising early results in urticaria study By Investing.com - Investing.com UK
Finanzdaten der Jasper Therapeutics Inc-Aktie (JSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):